Pfizer and BioNTech vaccine with efficacy greater than 90%
The vaccine being developed by the North American Pfizer and the German BioNTech proved to be more than 90% effective in preventing covid-19 infections in phase 3 clinical trials, which is still ongoing, the pharmaceutical company announced. “Protection in patients was achieved seven days after the second of two doses and 28 days after the … Read more